Beijing Hotgen Biotech Hits Day Low at CNY 124.11 Amid Price Pressure

Beijing Hotgen Biotech Co., Ltd. experienced a notable decline today, with the stock dropping by 3.02% and reaching an intraday low of CNY 124.11. This performance stands in contrast to the China Shanghai Composite, which fell by only 0.82% on the same day. Over the past week, Beijing Hotgen has seen a more significant downturn, with a 7.36% decrease, and a 9.22% drop over the past month. Despite a strong performance over the past year, where the stock rose by 51.39%, the year-to-date performance reflects a decline of 23.37%. The company has faced challenges, including a 4.41% decrease in net sales and a concerning trend of negative results over the last 12 consecutive quarters. Financial metrics indicate a net profit of CNY -75.78 million, with a return on equity of -7.31%. As a large-cap player in the Pharmaceuticals & Biotechnology industry, Beijing Hotgen's market capitalization stands at CNY 12,588 million. The stock's current trading conditions suggest a heightened level of risk compared to its historical valuations.